Booths # 23-25 at the Annual Dialysis Conference -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, announced the latest interim results from its ongoing FREEDOM study, which show the significant improvement of overall sleep quality and marked improvement in Restless Legs Syndrome (RLS) experienced by patients after four months of daily home hemodialysis therapy with the NxStage System One™... (Source: Health News from Medical News Today)MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Booths # 23-25 at the Annual Dialysis Conference -- NxStage Medical, Inc... (Source: Medical Devices News From Medical News Today)

LAWRENCE, Mass. and SEATTLE, March 8 (HSMN NewsFeed) -- Booths # 23-25 at the Annual Dialysis Conference -- NxStage Medical, Inc. (Nasdaq:NXTM ), a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ... DevicesNxStage Medical, home hemodialysis, hemodialysis, Restless Legs Syndrome (Source: HSMN NewsFeed)

When conglomerates and consumer products lay off workers and employees, shareholders generally cheer the company for saving money and cutting costs by figuring out productivity measures that milk more output per employee.  That leaves more income and ultimately brings more dividends down the road.  But biotech firms are far from being thought of in the same light.  These are growth stories and investors generally get more excited about expanding operations.  So here comes XenoPort, Inc. (NASDAQ: XNPT) announcing on a Friday that HALF of its workers just won the pink-slip lotto ticket from the HR department.  Today just officially became National Employee Morale Day at XenoPort. XenoPort just announced a restructuring plan today that more narrowly focuses its R&D pipeline, and one ...

SANTA CLARA, Calif.--(HSMN NewsFeed)--XenoPort, Inc. (Nasdaq:XNPT ) announced today a restructuring that includes an overall reduction in its workforce of approximately 50%. The restructuring is designed to focus the Company’s resources on advancement of i... BiopharmaceuticalsXenoPort, Horizant, gabapentin, restless legs syndrome (Source: HSMN NewsFeed)

Zusammenfassung Hintergrund  Unterkieferprotrusionsschienen (UPS) stellen eine etablierte Methode in der Behandlung von Schnarchen (SN) und schlafbezogenen Atmungsstörungen (SBAS) dar. Ziel der Studie war die Erhebung der Langzeit- und Nebenwirkungen der IST®-Schiene (intraorale Schnarchtherapie) bei SN und SBAS sowie der Compliance der Patienten. Material und Methoden  60 im Schlaflabor auf die IST®-Schiene eingestellte Patienten wurden nach zumindest 2-jähriger Therapie postalisch kontaktiert. Ergebnisse  Die Fragebögen schickten 44 Patienten (33 Männer) von 43–83 Jahren (Mittelwert ± Standardabweichung: 63±10) zurück. Die Tragedauer der UPS betrug zwischen 24 und 75 (32±17) Monate, 77% verwendeten sie noch regelmäßig. ...MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Restless legs syndrome (RLS) is a highly prevalent movement disorder. However, prevalences seem to vary amongst different ethnicities. To date, no community-based prevalence studies on RLS have been reported from the African continent. We have conducted a community-based, door-to-door study in northern Tanzania. Over a period of 16 months, 7,654 people aged 14 years and older were screened for the RLS Essential Diagnostic Criteria. Sampling was performed according to the method of "multistage cluster sampling." People who screened positive where reinterviewed and physically examined by a specialist neurologist. During the screening phase, 10 people answered "yes" to at least one of the screening questions. After reinterviewing those people, the result was confirmed in five people only. Aft...

This study characterizes findings on sleep testing and Human Leukocyte Antigen (HLA) markers in a group of patients with fibromyalgia (FM) and chronic fatigue syndrome (CFS). One hundred eighteen patients seen in a general neurology practice over 5 years meeting standard clinical criteria for FM or CFS were analyzed retrospectively. Cases of untreated sleep apnea or restless legs syndrome were excluded prior to inclusion in this study. Ninety-two patients had multiple sleep latency testing (MSLT). Seventy-three (80%) were abnormal by standard criteria. Of 57 females having positive MSLTs, 22 (39%) had one or more periods of sleep onset rapid eye movement (SOREM), and 5 of 16 (31%) males with positive MSLTs had one or more SOREM. Highly fragmented sleep, as previously described in FM, was s...

Conclusions  The prevalence of RLS in cancer patients undergoing chemotherapy is 18.3%, about double of that expected in the general population. The occurrence of RLS is much more frequent in female patients and with longer-term chemotherapy. Cancer patients afflicted by RLS have significantly higher levels of anxiety and depression, and poorer quality of life especially in the physical well-being dimension. Recognition and treatment of RLS in cancer patients is an important target in clinical management and may improve quality of life and overall health outcomes in these patients. Content Type Journal ArticleDOI 10.1007/s11136-010-9614-8Authors Luca Ostacoli, University of Torino, San Luigi Hospital Mental Health Orbassano ItalyAndrea Saini, University of Torino, ...

(Source: Sleep)

Conclusions Among individuals with diabetes, RLS can impair mental health, increasing the risk for anxiety and depression. Since RLS consequences on nocturnal rest and psychological status may impair glycemic control in this population, diabetologists and diabetes educators should investigate for the presence of RLS in their patients and treat them. (Source: The Diabetes Educator)MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Conclusions: Together these results suggest that deficits in eyeblink conditioning are related to the pathophysiology of RLS. The eyeblink conditioning test may also be useful for supporting a clinical diagnosis or treatment strategy for RLS. (Source: Sleep Medicine)

Sleep problems are remarkably prevalent in patients with chronic kidney disease (CKD) . Numerous publications have demonstrated the high burden of sleep disorders in early stage disease, in patients on dialysis, and even in patients who have received renal transplants. Endstage renal disease (ESRD) produces dramatic compromise of patients’ quality of life, and sleep disorders represent a major and potentially treatable component of that impairment with implications for several quality of life indices, medication use, and even mortality . A survey of 883 dialysis patients from 20 Italian dialysis centers revealed that 80% endorsed symptoms of sleep disorders including 69.1% with insomnia, 23.6% with sleep apnea syndromes, 18.4% with restless legs, 11.8% with excessive daytime sleepiness, ...

Studies suggest that micronutrient depletion may contribute to neuropathic problems in ESRD patients. We assessed the relationship of RLS in individuals receiving chronic dialysis to their biotin status as judged by activity of a biotin-dependent enzyme, propiony-CoA carboxylase (PCC), in peripheral blood lymphocytes (PBL). 70patients and 8 control subjects participated. Diagnosis of RLS was made using the International Restless Legs Scale. PCC activity was measured by a14C-HCO3 incorporation assay and PCC activation coefficient (AC) was measured after ex vivo incubation of PBL with 10 nM biotin. PCC activity and PCC AC were not significantly different between the dialysis group and the control group., However, PCC AC did approach significance (p = 0.06). For PCC AC, 19/61 (31%) of the sub...

GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). A Complete Response letter is issued by the FDA's Center of Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form... (Source: Health News from Medical News Today)

GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS)... (Source: Pharma Industry News From Medical News Today)MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

We report a family (male index case, mother and maternal grandfather) with autosomal dominant inheritance of paroxysmal exercise-induced dystonia. The dystonia began in childhood and was only ever induced after many minutes of exercise, and was never present at rest, or on initiation of movements. In addition, family members suffered restless legs syndrome (RLS), depression, and adult-onset Parkinsonism. The index case had low cerebrospinal fluid neurotransmitters and pterins. The PED and RLS stopped on initiation of l-Dopa therapy. Both live family members were found to have a nonsense mutation (p.E84X) in exon 1 of the GTP-cyclohydrolase 1 (GCH-1) gene. We propose that GCH-1 mutations should be considered a genetic cause of familial PED, especially if additional clinical features of mono...

GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). (Source: World Pharma News)

GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). A Complete Response letter is issued by the FDA's Center of Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form... (Source: Health News from Medical News Today)

GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS)... (Source: Public Health News From Medical News Today)